New drug for common liver disease improves liver health

On November 7, 2014, the NIH reported that “the FLINT study found that people with nonalcoholic steatohepatitis (NASH) who took obeticholic acid (OCA) had improved liver health during that period, including decreased inflammation and fat in the liver and decreased body weight versus people receiving a placebo. OCA was also associated with increases in itching and total cholesterol.” To learn more, click here.

Filed Under: Repost

About the Author: JSNMA is the flagship publication of the Student National Medical Association (SNMA). As the voice of the SNMA, it serves as an educational and outreach tool to upcoming doctors and researchers. Journal topics include medical education, research, health advocacy, career opportunities, cultural competency and community outreach.

RSSComments (0)

Trackback URL

Comments are closed.